GO
Loading...

Eli Lilly and Co

More

  • It didn't take long for Japan's Takeda Pharmaceuticals, which trades on the Tokyo exchange, to try to capitalize on the new safety warning for GlaxoSmithKline's diabetes drug Avandia. Last week the FDA slapped a so-called "Black Box"--the agency's most severe warning--on the Avandia label advising patients and doctors about the potential heart attack and stroke risk that's been the subject of so much controversy over the past several months.

  • If the writer's strike has you looking for alternatives to insomnia-fighting late-night TV shows, then Pfizer may have just what the doctor ordered. Tune into the company's web cast for investors and analysts at 11 p.m. Eastern Daylight Savings Time on Thursday, November 29th. If you don't believe me check out the press release on the Pfizer web site. The world's biggest drug company is taking its show on the road to Hong Kong.

  • Pharma Stocks To Watch On Monday (And My Time Off) Sunday, 4 Nov 2007 | 12:57 PM ET

    I'm taking some much needed time off for a couple of weeks. Actually, our scheduling guru at CNBC, Alex Crippen, told me if I don't use all of the days I've accumulated by the end of next month, I'll lose them. I consider myself a hard worker, but I'm not that generous. So, off I go.

  • Eli Lilly: Will They Get Lucky With 'One A Day' Cialis? Wednesday, 31 Oct 2007 | 3:36 PM ET
    Eli Lilly

    Today's the day Eli Lilly was expected to get a Food and Drug Administration decision on the first-ever one-a-day impotence drug. Right now, the company sells Cialis for use as needed. But men could pop this one every day--like an aspirin or multi-vitamin--so the drug would always be "on boa

  • Amylin's Once A Week Byetta: Good Is Not Enough Wednesday, 31 Oct 2007 | 12:21 PM ET
    Byetta Needle

    This morning Amylin Pharmaceuticals, Eli Lilly and Alkermes announced the highly anticipated test results on their once-a-week, Type 2 diabetes drug. One analyst recently called this the most important biotech data of the second half of this year. Many expect the drug to become a multi-billion dollar blockbuster.

  • Stocks Edge Lower After Seesaw Day Thursday, 25 Oct 2007 | 4:26 PM ET

    Stocks finished near even Thursday as Wall Street endured another topsy-turvy session, with rumors – of more subprime trouble and a Fed rate cut – proving just as influential on the markets as a handful of economic and earnings reports.

  • Lilly Stock Drops on Halted Clot Drug Trials Thursday, 25 Oct 2007 | 11:51 AM ET

    Shares of Eli Lilly fell more than 6 percent on Thursday, after the drugmaker halted two small trials of blood clot preventer prasugrel, the company's most important experimental drug.

  • Eli Lilly: "Bloom" Is Off The Pipeline Thursday, 25 Oct 2007 | 11:43 AM ET
    Eli Lilly

    If the stock closes down at least 4.46% today (as I write this it is off nearly 7%) Eli Lilly will suffer its worst one-day loss in more than four years, according to our resident statistical expert Robert Hum. If it were to close off more than 7.79%, Hum says it would be the stock's biggest one-day fall since Oct. 23, 2002--almost five years to the day.

  • Bristol-Myers Profit Jumps on Higher Drug Revenue Thursday, 25 Oct 2007 | 9:00 AM ET

    Bristol-Myers Squibb Thursday said third-quarter earnings more than doubled on higher drug revenue, including a strong rebound for its Plavix blood-clot preventer, and raised its 2007 profit forecast.

  • Huckman's Drug Headlines Wednesday, 24 Oct 2007 | 7:27 PM ET

    Lots of late news from the drug makers. CNBC’s Mike Huckman has the latest.

  • Eli Lilly Halts Two Drug Studies; Shares Fall Wednesday, 24 Oct 2007 | 6:50 PM ET

    Eli Lilly said it stopped giving its experimental blood-clot preventer prasugrel to heart patients in two small trials, noting that the dosage of the drug may have to be adjusted for certain types of patients.

  • Drug Earnings Deluge Thursday, 18 Oct 2007 | 7:01 PM ET

    The Big Pharma earnings season is in full swing with Pfizer (PFE), Eli Lilly (LLY) and Wyeth (WYE) out Thursday and Merck (MRK) and Schering-Plough (SGP) reporting Monday. What’s the trade as the drug companies deal with their ailing pipelines?

  • Impotence Drugs to Add Warning About Hearing Loss Thursday, 18 Oct 2007 | 5:13 PM ET
    Pfizer's Viagra

    U.S. regulators said warnings about the risk of sudden hearing loss linked to popular drugs for impotence, including Viagra, Cialis and Levitra, would be added to the drugs' labels.

  • Stocks ended mixed as Bank of America's earnings shortfall was countered by strong tech and healthcare earnings. "In the last few days there is more concern about this bleeding into the fourth quarter, with the Bank of America comments and housing having more of a negative impact on the consumer than maybe we've seen so far," said Alec Young, equity strategist at S&P.

  • Pfizer "Chokes" on Inhaled Diabetic Insulin Thursday, 18 Oct 2007 | 11:29 AM ET
    Exubera

    Just months after launching what was hailed as a revolutionary new product, Pfizer is taking it off the market. And it has nothing to do with safety. It has everything to do with sales--or the lack, thereof. The world's biggest drug company only recently started direct-to-consumer advertising for Exubera, but it apparently didn't work.

  • Pharma Profit Roundup: Pfizer, Lilly and Wyeth Thursday, 18 Oct 2007 | 10:24 AM ET

    How's the health of Big Pharma? Not bad, judging from Pfizer, Eli Lilly and Wyeth results. Still, the drug market leaders could use some diet and exercise, here and there ...

  • Lilly Profit Rises on Sales of Newer Drugs Thursday, 18 Oct 2007 | 9:25 AM ET

    Eli Lilly said Thursday third-quarter profit rose on higher sales of newer prescription drugs, including its Cymbalta anti-depressant, and the company raised its 2007 forecast.

  • Market Insider: Techs Catch the Big Fish Wednesday, 17 Oct 2007 | 8:29 PM ET

    Technology has been a big lure in an otherwise fishy stock market this week.

  • Amylin, Eli Lilly Shares Slip On Diabetes Drug Worries Tuesday, 16 Oct 2007 | 1:52 PM ET

    The U.S. Food and Drug Administration said it had reviewed 30 reports of pancreatitis in patients taking Byetta, known generically as exenatide.

  • Alzheimer's Blood Test: Would You Take It? Monday, 15 Oct 2007 | 1:52 PM ET
    Cat scan image of human brain

    This morning on "Squawk Box" and "Squawk on the Street" I reported on a new study showing that a simple blood test might predict whether you will develop Alzheimer's Disease. The report, which appears in the scientific, peer-reviewed journal "Nature Medicine...